The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment DOI Creative Commons
Anna V. Gorodilova, Kristina V. Kitaeva, Ivan Y. Filin

et al.

Current Issues in Molecular Biology, Journal Year: 2023, Volume and Issue: 45(10), P. 8053 - 8070

Published: Oct. 1, 2023

Since the discovery of dendritic cells (DCs) in 1973 by Ralph Steinman, a tremendous amount knowledge regarding these innate immunity has been accumulating. Their role regulating both and adaptive immune processes is gradually being uncovered. DCs are proficient antigen-presenting capable activating naive T-lymphocytes to initiate generate effective anti-tumor responses. Although DC-based immunotherapy not yielded significant results, substantial number ongoing clinical trials underscores relevance DC vaccines, particularly as adjunctive therapy or combination with other treatment options. This review presents an overview current human DCs, their classification, functions distinct populations. The stepwise process developing therapeutic vaccines treat oncological diseases discussed, along speculation on potential combined approaches modern immunotherapy.

Language: Английский

Glioblastoma vaccines: past, present, and opportunities DOI Creative Commons
Zujian Xiong, Itay Raphael, Michael R. Olin

et al.

EBioMedicine, Journal Year: 2024, Volume and Issue: 100, P. 104963 - 104963

Published: Jan. 5, 2024

Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in adults. As supplements to standard care (SOC), various immunotherapies improve therapeutic effect other cancers. Among them, tumour vaccines can serve as complementary monotherapy or boost clinical efficacy with immunotherapies, such immune checkpoint blockade (ICB) and chimeric antigen receptor T cells (CAR-T) therapy. Previous studies GBM have suggested that few neoantigens could be targeted due low mutation burden, single-peptide vaccination had limited control monotherapy. Combining diverse antigens, including neoantigens, tumour-associated antigens (TAAs), pathogen-derived optimizing vaccine design strategy may help improvement. In this review, we discussed current platforms, evaluated potential antigenic targets, challenges, perspective opportunities for

Language: Английский

Citations

31
Immunotherapy for glioblastoma: current state, challenges, and future perspectives DOI Creative Commons
Yang Liu, Zhou Fei, Heba Ali

et al.

Cellular and Molecular Immunology, Journal Year: 2024, Volume and Issue: 21(12), P. 1354 - 1375

Published: Oct. 15, 2024

Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The standard care offers minimal clinical benefit, most GBM patients experience recurrence after treatment. In recent years, significant advancements have been made the development novel immunotherapies or other therapeutic strategies that can overcome immunotherapy resistance many advanced cancers. However, benefit immune-based treatments limited because unique immune profiles, cell heterogeneity, immunosuppressive microenvironment. this review, we present a detailed overview current immunotherapeutic discuss challenges potential molecular mechanisms underlying GBM. Furthermore, provide in-depth discussion regarding GBM, which will likely require combination therapies.

Language: Английский

Citations

22
Basic helix–loop–helix ARNT like 1 regulates the function of immune cells and participates in the development of immune-related diseases DOI Creative Commons
Fanglin Shao, Zhipeng Wang,

Luxia Ye

et al.

Burns & Trauma, Journal Year: 2025, Volume and Issue: 13

Published: Jan. 1, 2025

The circadian clock is an internal timekeeper system that regulates biological processes through a central and peripheral clocks controlling various genes. Basic helix-loop-helix ARNT-like 1 (BMAL1), also known as aryl hydrocarbon receptor nuclear translocator-like protein (ARNTL1), key component of the clock. deletion BMAL1 alone can abolish rhythms human body. plays critical role in immune cell function. Dysregulation linked to immune-related diseases such autoimmune diseases, infectious cancer, vice versa. This review highlights significant governing cells, including their development, differentiation, migration, homing, metabolism, effector functions. study explores how dysregulation have far-reaching implications potentially contribute onset sepsis, trauma. Furthermore, this discusses treatments for target disorders. Understanding impact on function provide insights into pathogenesis help development more effective treatment strategies. Targeting has been demonstrated achieve good efficacy indicating its promising potential targetable therapeutic these diseases.

Language: Английский

Citations

4
Current approaches in glioblastoma multiforme immunotherapy DOI
Marjan Aghajani, Nazila Jalilzadeh, Ali Aghebati‐Maleki

et al.

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: 26(7), P. 1584 - 1612

Published: March 21, 2024

Language: Английский

Citations

13
Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication DOI Creative Commons
Ana Borrajo

Life, Journal Year: 2025, Volume and Issue: 15(2), P. 276 - 276

Published: Feb. 11, 2025

Recent advances in virology, particularly the study of HIV-1, have significantly progressed pursuit a definitive cure for disease. Emerging therapeutic strategies encompass innovative gene-editing technologies, immune-modulatory interventions, and next-generation antiretroviral agents. Efforts to eliminate or control viral reservoirs also gained momentum, with aim achieving durable remission without continuous requirement therapy. Despite these promising developments, critical challenges persist bridging gap between laboratory findings clinical implementation. This review provides comprehensive analysis recent breakthroughs, ongoing trials, barriers that must be addressed translate advancements into effective treatments, emphasizing multifaceted approaches being pursued achieve curative solution HIV-1 infection.

Language: Английский

Citations

1
Recent Advances in Biomimetic Strategies for the Immunotherapy of Glioblastoma DOI

Haoyu You,

Shuo Geng,

Shangkuo Li

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 311, P. 122694 - 122694

Published: June 28, 2024

Language: Английский

Citations

8
An overview of lipid constituents in lipid nanoparticle mRNA delivery systems DOI

Shiqi Wu,

Lixin Lin, Lu Shi

et al.

Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, Journal Year: 2024, Volume and Issue: 16(4)

Published: July 1, 2024

Abstract mRNA therapeutics have shown great potential for a broad spectrum of disease treatment. However, the challenges mRNA's inherent instability and difficulty in cellular entry hindered its progress biomedical field. To address barriers deliver to cells interest, various delivery systems are designed. Among these, lipid nanoparticles (LNPs) stand out as most extensively used systems, particularly following clinical approvals corona virus 2019 (COVID‐19) vaccines. LNPs comprised ionizable cationic lipids, phospholipids, cholesterol, polyethylene glycol derived lipids (PEG‐lipids). In this review, we primarily summarize recent advancements LNP technology, focusing on structures four constituents their applications. We delve into structure–activity relationships while also exploring future prospects developing more efficacious systems. This article is categorized under: Therapeutic Approaches Drug Discovery > Emerging Technologies Biology‐Inspired Nanomaterials Lipid‐Based Structures Nanotechnology Biology Nanoscale Systems

Language: Английский

Citations

8
Principles of lipid nanoparticle design for mRNA delivery DOI Creative Commons
Yiran Zhang, Xinyue Zhang, Yongsheng Gao

et al.

BMEMat, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 19, 2024

Abstract mRNA therapeutics have significantly evolved within the life sciences, particularly in applications such as vaccines, tumor immunotherapy, protein replacement, gene editing, and monoclonal antibody therapy. To fully realize potential of drugs mitigate adverse effects, substantial vector materials been developed for delivery these pharmaceutical agents. Lipid nanoparticles (LNPs) represent most clinically advanced carriers, recognized by U.S. Food Drug Administration approved vaccines numerous clinical trials. Diverse therapeutic necessitate tailored design LNPs. Herein, we outline principles LNP delivery, focusing specifically on their effectiveness, targeting capabilities, safety profiles, nanoparticle stability. Additionally, present latest advancements mRNA‐LNP technology. This review aims to elucidate benefits systems therapeutics, providing insights into breakthroughs innovative ideas further enhancing advantages. These summaries are dedicated promoting broader LNP‐mRNA drugs, aiming advance treatment serious diseases an effective safe manner.

Language: Английский

Citations

6
Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines DOI Creative Commons
Feng Lin,

Emma Z. Lin,

Misa Anekoji

et al.

Journal of Translational Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Nov. 18, 2023

Abstract Advancing personalized medicine in brain cancer relies on innovative strategies, with mRNA vaccines emerging as a promising avenue. While the initial use of was oncology, their stunning success COVID-19 resulted widespread attention, both positive and negative. Regardless politically biased opinions, which relate more to antigenic source than form delivery, we feel it is important objectively review this modality relates cancer. This class trigger robust immune responses through MHC-I MHC-II pathways, prophylactic therapeutic settings. The platform offers advantages rapid development, high potency, cost-effectiveness, safety. provides an overview vaccine delivery technologies, tumor antigen identification, combination therapies, recent outcomes, particular focus Combinatorial approaches are vital maximizing efficacy, ongoing clinical trials exploring combinations adjuvants checkpoint inhibitors even adoptive cell therapy. Efficient neoantigen preclinical studies, trial results highlighted, underscoring vaccines' potential advancing for Synergistic combinatorial therapies play crucial role, emphasizing need continued research collaboration area.

Language: Английский

Citations

12
Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma DOI Creative Commons
Bryan Gardam, Tessa Gargett, Michael P. Brown

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Oct. 20, 2023

Glioblastoma is an aggressive primary brain tumor that has seen few advances in treatments for over 20 years. In response to this desperate clinical need, multiple immunotherapy strategies are under development, including CAR-T cells, immune checkpoint inhibitors, oncolytic viruses and dendritic cell vaccines, although these approaches yet yield significant benefit. Potential reasons the lack of success so far include immunosuppressive microenvironment, blood-brain barrier, systemic changes system driven by both its treatment. Furthermore, while T cells essential effector control, play equally important role activation, emerging evidence suggests compartment may be deeply compromised glioblastoma patients. review, we describe currently development challenges faced, with a particular emphasis on critical cell-T axis. We suggest number could used boost function propose use combination cell-targeting lead successful control.

Language: Английский

Citations

11